Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
solid tumor
Biotech
Poseida examines CAR-T conditioning to crack into solid tumors
Why haven’t CAR-T therapies cracked into solid tumors yet? Poseida Therapeutics is trying to fill in at least one piece of the puzzle at AACR.
Annalee Armstrong
Apr 10, 2024 10:32am
Synthekine hopes new IL-2 will be the high-alpha in a beta class
Apr 10, 2024 9:50am
BMS-backed TORL grabs $158M to march army of ADCs through clinic
Apr 10, 2024 9:35am
Ipsen joins ADC race via $900M biobuck deal with Sutro
Apr 2, 2024 7:26am
Tubulis rides wave of ADC interest to $138M financing round
Mar 14, 2024 9:12am
BMS exits next-gen Yervoy pact, taking $300M in biobucks with it
Mar 12, 2024 7:07am